revenu ep beat consensu prompt increas guidanc
soliri launch gmg best prior launch ahu pnh ultomiri track
februari approv optimist rapid convers onto ultomiri
increas investor appreci prospect long-term revenu growth
revenu ep beat consensu prompt manag increas guidanc
third quarter row full recap earn see previou note total
revenu y/i vs consensu driven double-digit
volum growth y/i partial off-set fx headwind price headwind
manag note price headwind mostli caus price declin
turkey brazil follow soliri reimburs agreement subsequ attain
market author turkey brazil revenu also
unfavor impact order time relat juli holiday
tender order mostli ex-u rel product sale growth deriv
 y/i asia pacif row
soliri sale q/q y/i vs consensu driven
y/i volum growth though unfavor impact approxim
pull due pre-juli order time manag believ roughli half ahu
pnh patient yet initi treatment
strensiq y/i vs revenu less line
consensu due volum growth y/i germani off-set
unfavor impact due order time ahead juli holiday kanuma
revenu vs also consensu y/i volum
growth partial counter unfavor impact also due order
time ahead juli
alexion increas financi guidanc includ total revenu
soliri revenu non-gaap oper
margin non-gaap ep
consist guidanc increas estim soliri
total revenu non-gaap oper margin non-
gaap ep dcf-base price target increas
pleas see page report import disclosur
alexion new manag team restor investor confid underli demand trend
soliri remain solid launch gmg set eclips launch pnh
ahu expect fear competit alexion key complement franchis wain
alexion complement franchis transfer follow earli launch
strensiq wit strong launch appear destin blockbust statu
asset plu minor contribut kanuma allow compani
post industry-lead financi view alexion premier orphan diseas compani
expect share appreci investor gain convict soliri launch
initi phase registr trial
fda approv pnh
regulatori submiss soliri
nmosd eu japan earli
soliri sale transfer
strensiq kanuma lal-d
achiev
transit franchis
rapid assum
soliri fall short
commerci regulatori setback
strensiq
soliri experi meaning
soliri approv treatment paroxysm nocturn hemoglobinuria pnh
atyp hemolyt urem syndrom ahu pnh autoimmun
disord mark red blood cell deplet believ affect estim
patient world-wide candid soliri given price
approxim estim ww peak annual sale
pnh ahu caus overactiv complement pathway often kidney
soliri shown improv multipl hallmark diseas believ
ahu market could larger pnh market soliri also approv gener
myasthenia gavi gmg octob potenti new oppi beyond soliri strensiq
kanuma achiev commerci success respect
end alexion report gmg patient initi treatment
soliri enrol onesourc manag consid first year
launch success outpac pnh ahu launch appear
slow alexion continu see approxim net patient addit
week suggest movement onesourc onto soliri treatment continu apac
alexion commerci effort focus refractori gmg patient compani
receiv posit feedback physician manag note discontinu
track week seen pivot trial indic
drug clinic benefit consid competit landscap -- potenti
ultomiri -- gmg manag note infus well-receiv patient
mani view self-inject burdensom due weak
fatigu associ condit alexion plan initi trial ultomari iv
gmg earli
outsid alexion look appli learn order improv
uptak specif alexion recent made adjust sale educ initi
better explain role complement creat broader effect kol
engag manag hope initi speed uptak germani
japan gmg launch slower like due lack site
clinic trial experi promot strong launch canada soliri recent
approv gmg
late last month alexion announc top-lin result phase prevent trial
soliri auto antibody-posit neuromyel optica spectrum disord
nmosd primari endpoint time first adjud on-trial relaps soliri
reduc risk relaps rel placebo week hr
patient soliri relaps free rel patient placebo
safeti profil consist seen previous soliri clinic trial real-world
use case meningococc infect full data anticip futur medic
confer potenti alexion prepar regulatori flling
japan slate submiss earli conduct fda meet
alexion process refin address nmosd popul estim
tent alexion believ approxim nmosd patient
meet criteria high diseas activ approxim patient
test posit antibodi approxim antibodi
treat lead potenti address popul
morn call manag note test includ latest treatment
guidelin nmosd updat test increas awar
diagnosi condit alexion believ soliri potenti best-in-class
enter market first approv therapi nmosd said manag
believ opportun multipl therapi treat condit
alexion expand neurolog sale forc partial anticip nmosd
opportun expect synergi gmg nmosd call point compani
process identifi nmosd center excel order target sever
nmosd patient high unmet need
alexion initi launch prepar ultomiri pnh intern
alexion train commerci medic team prepar case manag
develop clinic data payer dossier support facilit convers launch
extern compani develop deeper understand healthcar provid
pnh patient dynam engag payer convers payer alexion
highlight ultomiri valu demonstr phase trial addit direct
 infus vs soliri indirect greater knockdown improv
patient symptom cost save associ treatment though alexion lock
specif price manag note feedback promis estim
soliri averag ultomiri price modest
discount facilit rapid convers
competit front roche/chugai announc present data
decemb recal long-act recycl mab
similar soliris/ultomiri structur function yet immunogen
hypersensit reaction two patient on-going clinic trial led temporari
halt enrol germani franc itali may detract drug
competit profil furthermor today call manag highlight
target differ epitop ultomiri soliri switch patient
soliri might involv consider beyond involv convert patient
regeneron present phase data pnh once-weekli subq
pozelimab well regeneron plan move pozelimab phase ii
trial pnh behind alexion registr trial subq ultomiri set initi
alexion also present abstract total oral phase ultomiri
program
dicerna agreement announc morn allow alexion target upstream
complement factor produc liver subq administr infrequ
dose serum complement protein predominantli synthes liver though
local synthesi certain cell type contribut complement compon bodi
fluid intracellular space alexion believ dicerna technolog de-
risk demonstr proof-of-concept primari hyperoxaluria condit excess
oxal product liver view agreement one expand option
supplement compani intern discoveri platform
last month alexion announc agreement acquir syntimmun
fcrn-target product treat igg-medi diseas stage develop
manag believ compar competitor fcrn-target therapi
differ level affin fcr assum compar safeti profil
believ first-mov advantag matter captur market share igg-
mediat indic alexion look first market warm autoimmun hemolyt
anemia waiha diseas approv therapi anti-fcrn asset
clinic develop data on-going phase ib/iia studi pemphigu vulgari
expect point alexion plan initi pivot program pivot trial
anoth undisclos indic also slate next year
alexion continu execut grow base busi expand pipelin
reflect compani result give alexion credit
impress launch gmg expect continu apac nonetheless
despit alexion strong financi perform stock today investor
appear concern like data compet complement program
other worri guidanc impli modest growth and/or slow
margin improv frankli think big portion weak due bad
biotech tape nbi biotech sentiment quickli come reflect
glass half empti view event neither concern hear investor
deriv new revel alexion rais guidanc prior three
quarter guidanc conserv fact roch rhhbi scala
expect releas data program known said
clear prospect competit alexion complement franchis
overhang unless investor becom convinc alexion competit
posit hope rapid convers soliri pnh sale ultomiri
begin persuad investor franchis defens
current assum would posit share potenti re-rat investor
consid alexion compani good prospect long term growth
soliri eculizumab human monoclon antibodi approv
treatment paroxysm nocturn hemoglobinuria pnh atyp hemolyt
urem syndrom ahu gener myasthenia gravi gmg
soliri becom one success ultra-orphan drug sale
y/i pivot trial soliri neuromyel optica nmo releas
posit phase data registr file eu japan
plan earli next-gener soliri candid ultomiri seek
advanc upon soliriss profil offer greater conveni potenc
phase studi use dose paradigm demonstr non-
inferior soliri trend superior regulatori file
eu submit around fda give ultomiri
also set begin registr trial late alexion also initi
phase trial subq co-administ halozym
call could extend dose interv given
steadi new patient add stabl price ultomiri
abil protect franchis competit estim sale
alexion complement franchis includ pnh
ahu gmg alexion market two addit ultra-orphan drug
strensiq asfotas alfa hypophosphatasia sever bone diseas
approv europ japan gener sale
believ drug potenti alexion acquir synageva
bring kanuma enzym replac therapi lal
defici unfortun alexion face challeng identifi lal-d
patient sale like far modest expect model
sale alexion also acquir wilson therapeut april
gain access treatment wilson diseas current phase
develop addit septemb alexion announc agreement
acquir syntimmun alexion aim move pivot
develop warm autoimmun hemolyt anemia waiha view alexion
premier orphan diseas compani expect share appreci investor
gain convict growth prospect alexion complement franchis
cowen compani
reportedcowen estimatesoliri percent percent percent cowen
execut gmg launch japan germani other
regulatori submiss soliri nmosd eu japan
launch addit ex-u territori uk franc israel canada
launch addit ex-u territori
initi registr bridg trial subq formul
top-lin data phase trial ahu
initi phase ultomiri iv gmg
file approv ahu
acquir in-licens addit earli stage candid
cowen compani
cowen compani
franchis y/i y/i y/i y/i sale y/i y/i y/i gross total product oper oper oper incom non- tax net incom y/i base compens incom includ stock includ stock comp ep exclud stock comp expens non-cash tax amort acquir intang cost associ acquisit ep cowen
cowen compani
franchis sale kanuma sale y/i gross total gener product oper incom tax net y/i includ stock comp ep exclud stock comp expens non-cash tax amort acquir intang cost associ acquisit ep cowen
cowen compani
oper activitiesnet incom net use oper activitiesnon-cash exit currency/hedg lossshare-bas compens conting gain loss forward contractsdef asset liabilitiesaccount expens payable/accru use oper invest activitieschang market acquisitionspurchas invest financ activitiesdebt issuanc excess tax benefit stock option mortagag note payableproce loan stock proce issuanc common stock financ fx chang cash equival begin cash equival end summari oper itemsbegin cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
great major alexion valu deriv singl product soliri risk
expect soliri includ potenti slowdown pnh market unknown
size ahu market regulatori clinic develop risk indic
includ nmo mg alexion share could also wit meaning downsid
meet failur
